• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of molecular imaging >Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue
【24h】

Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue

机译：标记生长抑素类似物对食管癌进行影像学检查的可行性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. While the surface of a cell normally has some amount of somatostatin receptors, these receptors are overexpressed to a very high degree in multiple neoplastic diseases. No data exist for esophageal carcinoma.Purpose. To find out whether esophageal carcinoma could be imaged using somatostatin receptor scintigraphy.Material and Methods. 34 patients with esophageal lesions were prospectively examined by99mTc-depreotide scintigraphy 2 and 4 hours after injection. Quantitative evaluation of99mTc-depreotide uptake was performed around the lesion (T) and in healthy lung parenchyma (B). The relative uptake was calculated asT−B/B. Scintigraphy results were compared with histopathology from surgery or biopsy specimens from endoscopic ultrasonography.Results. 21 patients had esophageal cancer, and 13 lesions were benign. Visual assessment revealed positive99mTc-depreotide uptake in 16 of the 21 cancers. The 13 patients without cancer had no depreotide uptake. The Mann-Whitney U test showed a statistically significant difference (P<.005) between99mTc-depreotide uptake in malignant and benign lesions, for both the 2-hour and the 4-hour measurements.Conclusion. Scintigraphic examination with99mTc-depreotide is feasible for imaging esophageal cancer, but the method is not suitable neither for screening or primary diagnosis, because of methods modest sensitivity. Our first results showed high specificity which should be used with caution, as the number of patients was relatively low. Further studies are needed to determine the role of the method.
机译：背景。虽然细胞表面通常具有一定数量的生长抑素受体，但在多种肿瘤疾病中，这些受体过表达程度很高。没有食管癌的数据。使用生长抑素受体闪烁显像技术检查食管癌是否可以成像。材料与方法。注射后2和4小时，通过99mTc-去甲肽闪烁显像对34例食管病变患者进行前瞻性检查。在病灶周围（T）和健康的肺实质（B）中对99mTc-去甲肽的摄取进行了定量评估。相对摄入量计算为TB / B。将闪烁显像的结果与手术的组织病理学或内窥镜超声检查的活检标本进行比较。食道癌21例，良性病变13例。视觉评估显示21种癌症中的16种中正摄取99mTc-prepreotide。 13名无癌患者均未接受prepreotide吸收。 Mann-Whitney U检验显示，在2小时和4小时的测量中，恶性和良性病变中99mTc-去甲肽的摄取之间在统计学上有显着差异（P <.005）。用99mTc-depreotide进行闪烁成像检查对食管癌的影像学检查是可行的，但由于该方法灵敏度不高，因此不适用于筛查或初步诊断。我们的第一个结果显示出高特异性，由于患者数量相对较低，应谨慎使用。需要进一步研究以确定该方法的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号